Cargando…

Early Morning QT Prolongation During Hypoglycemia: Only a Matter of Glucose?

Detalles Bibliográficos
Autores principales:	D'Imperio, Sara, Monasky, Michelle M., Micaglio, Emanuele, Negro, Gabriele, Pappone, Carlo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8144311/ https://www.ncbi.nlm.nih.gov/pubmed/34046442 http://dx.doi.org/10.3389/fcvm.2021.688875

Ejemplares similares

The Mechanism of Ajmaline and Thus Brugada Syndrome: Not Only the Sodium Channel!
por: Monasky, Michelle M., et al.
Publicado: (2021)

Impact of Dietary Factors on Brugada Syndrome and Long QT Syndrome
por: D’Imperio, Sara, et al.
Publicado: (2021)

Brugada Syndrome: Warning of a Systemic Condition?
por: D'Imperio, Sara, et al.
Publicado: (2021)

Further Considerations in Childhood-Onset Hypertrophic Cardiomyopathy Genetic Testing
por: Monasky, Michelle M., et al.
Publicado: (2021)

Evaluating the Use of Genetics in Brugada Syndrome Risk Stratification
por: Monasky, Michelle M., et al.
Publicado: (2021)

Right ventricular electromechanical abnormalities in Brugada syndrome: is this a cardiomyopathy?
por: Pappone, Carlo, et al.
Publicado: (2020)

Brugada Syndrome: Oligogenic or Mendelian Disease?
por: Monasky, Michelle M., et al.
Publicado: (2020)

Common modulators of Brugada syndrome phenotype do not affect SCN5A prognostic value
por: Pappone, Carlo, et al.
Publicado: (2021)

The omics of channelopathies and cardiomyopathies: what we know and how they are useful
por: Pappone, Carlo, et al.
Publicado: (2020)

Commentary: Peptide-Based Targeting of the L-Type Calcium Channel Corrects the Loss-of-Function Phenotype of Two Novel Mutations of the CACNA1 Gene Associated With Brugada Syndrome
por: Monasky, Michelle M., et al.
Publicado: (2021)

Calcium in Brugada Syndrome: Questions for Future Research
por: Monasky, Michelle M., et al.
Publicado: (2018)

Role of Pharmacogenetics in Adverse Drug Reactions: An Update towards Personalized Medicine
por: Micaglio, Emanuele, et al.
Publicado: (2021)

QT Prolongation in Cancer Patients
por: Kim, Peter, et al.
Publicado: (2021)

Alterations of the Sialylation Machinery in Brugada Syndrome
por: Ghiroldi, Andrea, et al.
Publicado: (2022)

Right ventricular epicardial arrhythmogenic substrate in long-QT syndrome patients at risk of sudden death
por: Pappone, Carlo, et al.
Publicado: (2023)

Novel SCN5A p.Val1667Asp Missense Variant Segregation and Characterization in a Family with Severe Brugada Syndrome and Multiple Sudden Deaths
por: Monasky, Michelle M., et al.
Publicado: (2021)

Case report: Complex arterial findings in vascular ehlers-danlos syndrome with a novel COL3A1 variant and death at young age
por: Taurino, Jacopo, et al.
Publicado: (2023)

SCN5A Nonsense Mutation and NF1 Frameshift Mutation in a Family With Brugada Syndrome and Neurofibromatosis
por: Micaglio, Emanuele, et al.
Publicado: (2019)

The Prophylactic Effects of Metoprolol, Diltiazem, and Pilocarpine on Hypoglycemia-Induced Prolongation of QT Interval
por: Cagiltay, Eylem, et al.
Publicado: (2021)

Brugada syndrome genetics is associated with phenotype severity
por: Ciconte, Giuseppe, et al.
Publicado: (2020)

Clinical Considerations for a Family with Dilated Cardiomyopathy, Sudden Cardiac Death, and a Novel TTN Frameshift Mutation
por: Micaglio, Emanuele, et al.
Publicado: (2021)

Genotype–Phenotype Correlation in a Family with Brugada Syndrome Harboring the Novel p.Gln371* Nonsense Variant in the SCN5A Gene
por: Monasky, Michelle M., et al.
Publicado: (2019)

Novel JAG1 Deletion Variant in Patient with Atypical Alagille Syndrome
por: Micaglio, Emanuele, et al.
Publicado: (2019)

Genotype/Phenotype Relationship in a Consanguineal Family With Brugada Syndrome Harboring the R1632C Missense Variant in the SCN5A Gene
por: Monasky, Michelle M., et al.
Publicado: (2019)

Novel SCN5A p.V1429M Variant Segregation in a Family with Brugada Syndrome
por: Monasky, Michelle M., et al.
Publicado: (2020)

Association of QT interval-prolonging drugs with clinical trial eligibility in patients with advanced cancer
por: Rowe, Elizabeth J., et al.
Publicado: (2022)

Epicardial ablation in genetic cardiomyopathies: a new frontier
por: Pappone, Carlo, et al.
Publicado: (2019)

Non collider experiments results on Dark Matter
por: D'Imperio, Giulia, et al.
Publicado: (2022)

QT Interval Prolongation Is a Novel Predictor of 1-Year Mortality in Patients With COVID-19 Infection
por: Banai, Ariel, et al.
Publicado: (2022)

Corrected QT Interval Prolongation during Severe Hypoglycemia without Hypokalemia in Patients with Type 2 Diabetes
por: Beom, Jae Won, et al.
Publicado: (2013)

Interleukin-6 Elevation Is a Key Pathogenic Factor Underlying COVID-19-Associated Heart Rate-Corrected QT Interval Prolongation
por: Lazzerini, Pietro Enea, et al.
Publicado: (2022)

Commentary: Next Generation Sequencing and Linkage Analysis for the Molecular Diagnosis of a Novel Overlapping Syndrome Characterized by Hypertrophic Cardiomyopathy and Typical Electrical Instability of Brugada Syndrome
por: Monasky, Michelle M., et al.
Publicado: (2017)

Novel SCN5A p.W697X Nonsense Mutation Segregation in a Family with Brugada Syndrome
por: Micaglio, Emanuele, et al.
Publicado: (2019)

QT prolongation with methadone
por: Dhamija, Radhika, et al.
Publicado: (2008)

Declining Levels and Bioavailability of IGF-I in Cardiovascular Aging Associate With QT Prolongation–Results From the 1946 British Birth Cohort
por: Charalambous, Christos, et al.
Publicado: (2022)

Novel SCN5A Frameshift Mutation in Brugada Syndrome Associated With Complex Arrhythmic Phenotype
por: Micaglio, Emanuele, et al.
Publicado: (2019)

Assessing QT interval in COVID-19 patients:safety of hydroxychloroquine-azithromycin combination regimen
por: Bernardini, Andrea, et al.
Publicado: (2021)

Multifactorial QT Interval Prolongation and Takotsubo Cardiomyopathy
por: Gysel, Michael, et al.
Publicado: (2014)

Genome-wide Association Study of Susceptibility to Particulate Matter–Associated QT Prolongation
por: Gondalia, Rahul, et al.
Publicado: (2017)

The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study
por: Ring, Arne, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_on8e8li74vmiouurhi6qetdmuj